{"id":"hit-skk-chemotherapy-cycles-b1-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HIT-SKK (Hämato-Immunologische Therapie) is a complex polychemotherapy protocol used primarily in pediatric acute lymphoblastic leukemia (ALL) and other hematologic malignancies. The regimen employs multiple chemotherapy agents with different mechanisms—including topoisomerase inhibitors, alkylating agents, and anthracyclines—to maximize tumor cell kill through complementary pathways while managing resistance development.","oneSentence":"HIT-SKK is a multi-agent chemotherapy regimen combining doxorubicin, cyclophosphamide, etoposide, and other agents designed to treat pediatric hematologic malignancies through DNA damage and cell cycle disruption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:43.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric acute lymphoblastic leukemia (ALL)"},{"name":"Pediatric non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HIT-SKK Chemotherapy Cycles B1-3","genericName":"HIT-SKK Chemotherapy Cycles B1-3","companyName":"Nationwide Children's Hospital","companyId":"nationwide-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HIT-SKK is a multi-agent chemotherapy regimen combining doxorubicin, cyclophosphamide, etoposide, and other agents designed to treat pediatric hematologic malignancies through DNA damage and cell cycle disruption. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}